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Background: With development of resistance to new gen-
eration antibiotics, very few therapeutic options are left in the
arsenal against Staphylococcus aureus. Virulence factors and resis-
tant traits emerging in the hospital and in community acquired
infections favor colonization and pathogenesis. BBIL-5 is a potent
anti-Staphylococcalprotein that kills S.aureusof anyantibiotic resis-
tance proﬁle.
Methods & Materials: Minimum inhibitory concentration
(MIC) of S.aureus clinical isolates to BBIL-5 was estimated by
broth dilution method. Antibiotic susceptibility was determined
by Stoke’s method and by disk diffusion studies. Synergy with
antibiotics was demonstrated by kill kinetics and in vivo in ani-
mal studies. Therapeutic dose regimenwas established by infection
with intraperitoneally administered 107-108 S.aureus, and sub-
sequent treatment with BBIL-5 (doses in mg/Kg body weight).
Pharmacokinetic/Pharmacodynamics (PK/PD) indices were deter-
mined for single and multiple doses administered intravenously in
mice and rabbits. BBIL-5 concentration in PK studies and antibodies
to the protein were estimated by ELISA. Recombinant production
of BBIL-5 in E.coli and product development has been advanced to
GMP. GLP pre-clinical toxicity studies are in progress.
Results: The MIC to BBIL-5 ranged from 2-32 ng/ml. No antibi-
otic cross resistance was observed. Standardized doses of BBIL-5
when administered intravenously in three bolus doses, q24h com-
pletely eradicated S.aureus infection in mice. A single therapeutic
dose of the GMP product provided 2–3 Log reductions in colony
forming units (CFU) of S.aureus. Synergywith beta lactams reduced
the therapeutic dose to one-ﬁfth of the standardizeddose. AUC/MIC
and Cmax/MIC were the pre-dominant PK/PD indices. A high ratio
of Cmax/AUC and AUC/MIC positively improved the outcome in
eradication of S.aureus. Pharmacokinetic proﬁle in animals showed
ﬁrst order kinetics of elimination where C vs. t graph is not lin-
ear, but is a decaying exponential, while Log C vs. t graph is linear.
Improved therapeutic efﬁcacy against systemic S.aureus infections
was achieved by reducing kel (elimination rate constant) by IV
infusion. The proteinwasminimally immunogenic due to short cir-
culating half-life. The GMP product was extensively characterized.
Conclusion: BBIL-5 is the ﬁrst investigational biotherapeutic of
its kindwith demonstrated efﬁcacy in treatingmulti-drug resistant
S.aureus infections.
http://dx.doi.org/10.1016/j.ijid.2016.02.319
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Background: Pseudomonas aeruginosa is one of the major
pathogens causing morbidity and mortality in hospital acquired
infections (HAI).MDRP. aeruginosaare resistant to3ormore classes
of antibiotics. In cUTI cases catheter associated infections are incur-
able by most of the antibiotics. Compound A a novel Leu-t-RNA
synthetase inhibitor showed efﬁcacy in mouse ascending urinary
tract infection (AUTI) model against P. aeruginosa bioﬁlms formed
on urinary catheters.
Methods & Materials: In this study we established a mouse
model of foreign body associated AUTI. A spiral polyethylene
tube (PT) was placed transurethrally into bladder without sur-
gical manipulation, followed by transurethral inoculation with
Pseudomonas aeruginosa 1594965 (MDR) strain. Scanning electron
microscopy (SEM) was done after 4h of inoculation of bacte-
ria and bacterial counts were taken in kidneys, bladders and
catheter pieces for respective samples. In vivo efﬁcacy of Com-
pound A was tested using this established model against P.
aeruginosa 1594965(Compound A MIC: 1g/ml, meropenem MIC:
32g/ml). Compound Awas tested at 30 and 220mg/kg SC q6h and
meropenem was tested at human simulated dose of 60 mg/kg SC
q6h. The treatment was initiated 4h post infection and continued
daily for 7 days. Bacterial counts of placebo 4h, 7 days and 7 days
treated group’s samples of kidneys, bladders and catheters were
calculated. Data was analysed using bacterial counts of each group
and compared with those of 4 h placebo control group.
Results: SEM showed good establishment of bioﬁlm in 4 h
samples. In foreign body associated mouse infection model. LRS
inhibitor Compound A at 30, 220 mg/kg SC q6h showed log10 dif-
ference of -2.38, -2.18 log10 CFU/kidney respectively compared to
4hplaceboandmeropenemat60mg/kgSCq6hwas inefﬁcacious. In
bladders this log difference was -2.30, -1.21, -0.78 respectively. On
catheteronlyCompoundAat220mg/kgSCq6hshowed log10 differ-
ence of -1.59 log10CFU/ml. No efﬁcacy was observed in remaining
groups
Conclusion: Efﬁcacy of Compound A in foreign body associated
mouse AUTI infection model against MDR Pseudomonas aeruginosa
1594965 proves its efﬁcacy on bioﬁlm. These results warrant its
further investigation in HAI associated Pseudomonas aeruginosa
infections.
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